- Home
- PLCE vs LCTX Comparison
PLCE vs LCTX Comparison
Compare PLCE & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLCE
- LCTX
- Stock Information
- Founded
- PLCE 1969
- LCTX 1990
- Country
- PLCE United States
- LCTX United States
- Employees
- PLCE N/A
- LCTX N/A
- Industry
- PLCE Clothing/Shoe/Accessory Stores
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLCE Consumer Discretionary
- LCTX Health Care
- Exchange
- PLCE Nasdaq
- LCTX Nasdaq
- Market Cap
- PLCE 106.6M
- LCTX 118.8M
- IPO Year
- PLCE 1997
- LCTX N/A
- Fundamental
- Price
- PLCE $8.74
- LCTX $0.45
- Analyst Decision
- PLCE Hold
- LCTX Strong Buy
- Analyst Count
- PLCE 3
- LCTX 5
- Target Price
- PLCE $8.33
- LCTX $4.20
- AVG Volume (30 Days)
- PLCE 313.7K
- LCTX 1.8M
- Earning Date
- PLCE 04-11-2025
- LCTX 03-10-2025
- Dividend Yield
- PLCE N/A
- LCTX N/A
- EPS Growth
- PLCE N/A
- LCTX N/A
- EPS
- PLCE N/A
- LCTX N/A
- Revenue
- PLCE $1,432,740,000.00
- LCTX $9,499,000.00
- Revenue This Year
- PLCE N/A
- LCTX $25.10
- Revenue Next Year
- PLCE N/A
- LCTX $35.67
- P/E Ratio
- PLCE N/A
- LCTX N/A
- Revenue Growth
- PLCE N/A
- LCTX 6.19
- 52 Week Low
- PLCE $4.77
- LCTX $0.46
- 52 Week High
- PLCE $19.74
- LCTX $1.56
- Technical
- Relative Strength Index (RSI)
- PLCE 51.10
- LCTX 33.77
- Support Level
- PLCE $8.47
- LCTX $0.47
- Resistance Level
- PLCE $9.47
- LCTX $0.55
- Average True Range (ATR)
- PLCE 0.67
- LCTX 0.03
- MACD
- PLCE 0.16
- LCTX 0.00
- Stochastic Oscillator
- PLCE 72.03
- LCTX 11.21
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It design, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.